DexCom Inc. (DXCM)
Health Care3 articles
Market Mood
DEXCOM (DXCM) Files Form 144 on May 15, 2023
On May 15, 2023, Dexcom (DXCM) filed a Form 144 with the SEC. This form is typically used to notify the SEC of a proposed sale of stock by an affiliate. The specific details regarding the number of shares to be sold or the price were not disclosed. Such filings can indicate potential changes in stock ownership that may impact market perceptions and trading activity.
Read More
DexCom (DXCM) Trading at $64.62 with P/E Ratios 30.92 and 25.91
DexCom, Inc. (DXCM) shares traded at $64.62 as of April 20th. The company reported trailing and forward P/E ratios of 30.92 and 25.91, respectively. DexCom has achieved an average revenue growth of 17.4% annually over the past three years, with projections suggesting 15.2% growth ahead. The launch of the Stelo over-the-counter CGM and the G7 15-day sensor is expected to expand the market and improve gross margins to 63-64%, potentially increasing user retention and capturing millions of new insured lives. DexCom is targeting aggressive growth in international markets, particularly in Western Europe, Japan, and Australia.
Read More
Dexcom (DXCM) EVP Brown Sells $107K in Shares
Dexcom's (DXCM) Executive Vice President, Brown, sold shares worth $107,000. This transaction may raise questions among investors about future company performance and insider sentiment. Typically, large insider sales can influence market perception regarding the stock, particularly if there are no accompanying positive developments. The timing and context of such sales can also impact trading volumes and market reactions.
Read More